Innovent Biologics Inc. (IVBXF.OB) said that Phase 3 clinical trial results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with type 2 diabetes. Additionally, mazdutide treatment improved several cardiometabolic risk factors, including blood pressure, lipids, serum uric acid and liver enzymes.The trial results for mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-2) were presented as a late-breaking oral presentation at the 60th Annual Meeting of the European Association for the Study of Diabetes.Meanwhile, the first Phase 3 study results of mazdutide in the weight loss of overweight/obese subjects (GLORY-1) were reported in oral presentation session of EASD.

Innovent Biologics Inc.（IVBXF.OB）表示，3期临床试验结果表明，在中国2型糖尿病患者中，马杜肽在血糖控制和体重减轻方面均优于杜拉鲁肽。此外，mazdutide治疗改善了几种心脏代谢危险因素，包括血压，血脂，血尿酸和肝酶。在中国成人2型糖尿病（T2D）（DREAMS-2）患者中，胰高血糖素样肽-1受体（GLP-1R）和胰高血糖素受体（GCGR）双重激动剂mazdutide的试验结果在欧洲糖尿病研究协会第60届年会上作为最新的口头报告提交。同时，在EASD的口头报告会议上报告了马杜肽在超重/肥胖受试者体重减轻（GRORY-1）中的第一阶段3研究结果。

Mazdutide also works as a breakthrough weight-loss drug that offers dual-targeted fat burning, liver function improvement, and long-lasting weight reduction, providing comprehensive metabolic benefits to support weight loss and promote a healthier life.DREAMS-2 enrolled 731 Chinese participants with type 2 diabetes (mean age 51.8 years, mean baseline HbA1c 8.22%, mean baseline body weight 76.95 kg), whose diabetes was inadequately controlled with metformin alone or in combination with other oral anti-diabetic medications.

Mazdutide还可以作为一种突破性的减肥药物，提供双重靶向脂肪燃烧，肝功能改善和持久减肥，提供全面的代谢益处，以支持减肥并促进更健康的生活。DREAMS-2招募了731名中国2型糖尿病患者（平均年龄51.8岁，平均基线HbA1c 8.22%，平均基线体重76.95公斤），其糖尿病单独使用二甲双胍或与其他口服抗糖尿病药物联合使用控制不佳。

Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks. The primary endpoint was the change in HbA1c from baseline to week 28..

参与者被随机分配接受马珠肽4 mg，马珠肽6 mg或杜拉鲁肽1.5 mg，持续28周。。。

According to the company, after 28 weeks of treatment, mean reductions in HbA1c from baseline were 1.69% and 1.73% for mazdutide 4 mg and mazdutide 6 mg, respectively, demonstrating superiority over dulaglutide 1.5 mg (1.36%).After 28 weeks of treatment, participants treated with mazdutide 4 mg and mazdutide 6 mg experienced mean weight reductions of 9.24% and 7.13%, respectively, significantly outperforming dulaglutide (2.86%).For More Such Health News, visit rttnews.com.

据该公司称，治疗28周后，马珠肽4 mg和马珠肽6 mg的HbA1c平均比基线降低1.69%和1.73%，优于杜拉鲁肽1.5 mg（1.36%）。治疗28周后，服用马珠肽4 mg和马珠肽6 mg的参与者的平均体重分别减轻了9.24%和7.13%，明显优于杜拉鲁肽（2.86%）。欲了解更多此类健康新闻，请访问rttnews.com。